Quick Answer
Nautilus Biotechnology, Inc. reported Net Income Loss of -$59.00 million for the year ending 2025.
- Nautilus Biotechnology, Inc. showed an increase of +16.6% in Net Income Loss from 2024 to 2025.
- This data is from Nautilus Biotechnology, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $0.00 | Q2 2020: -$3.36 million | Q3 2020: -$3.98 million | Q1 2021: -$8.41 million | Q2 2021: -$10.71 million | Q3 2021: -$14.50 million | Q1 2022: -$15.76 million | Q2 2022: -$14.69 million | Q3 2022: -$14.06 million | Q1 2023: -$14.97 million | Q2 2023: -$15.81 million | Q3 2023: -$15.88 million | Q1 2024: -$18.73 million | Q2 2024: -$18.01 million | Q3 2024: -$16.45 million | Q1 2025: -$16.61 million | Q2 2025: -$15.03 million | Q3 2025: -$13.57 million.
- Over the full 6 years of available data (2020 to 2025), Nautilus Biotechnology, Inc.'s Net Income Loss has declined by 277.8%.
- Historical annual values: Fiscal year 2025: -$59.00 million | Fiscal year 2024: -$70.78 million | Fiscal year 2023: -$63.68 million | Fiscal year 2022: -$57.92 million | Fiscal year 2021: -$50.32 million | Fiscal year 2020: -$15.62 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: